Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chemotherapy Induced Nausea and Vomiting: Overview
Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.
“Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.
Chemotherapy Induced Nausea and Vomiting Emerging Drugs Chapters
This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Nausea and Vomiting Emerging Drugs
APD403: Acacia Pharma
APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. The drug is currently in Phase II clinical studies for Chemotherapy-induced nausea and vomiting.
CAM2047: Camurus
CAM2047 is along-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. It is currently under Phase I stage of development for the treatment of Chemotherapy-induced nausea and vomiting.
Further product details are provided in the report……..
Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chemotherapy Induced Nausea and Vomiting
There are approx. 15+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase II include, Acacia Pharma.
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.
Chemotherapy Induced Nausea and Vomiting Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chemotherapy Induced Nausea and Vomiting: Overview
Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.
“Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.
Chemotherapy Induced Nausea and Vomiting Emerging Drugs Chapters
This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Nausea and Vomiting Emerging Drugs
APD403: Acacia Pharma
APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. The drug is currently in Phase II clinical studies for Chemotherapy-induced nausea and vomiting.
CAM2047: Camurus
CAM2047 is along-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. It is currently under Phase I stage of development for the treatment of Chemotherapy-induced nausea and vomiting.
Further product details are provided in the report……..
Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chemotherapy Induced Nausea and Vomiting
There are approx. 15+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase II include, Acacia Pharma.
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.
Chemotherapy Induced Nausea and Vomiting Report Insights
- Chemotherapy Induced Nausea and Vomiting Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?
- How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?
- What are the key designations that have been granted to the emerging drugs?
- Acacia Pharma
- Camurus
- LP Pharmaceuticals
- Skye Bioscience
- TALLC Corporation
- Starton Therapeutics
- APD403
- CAM2047
- Palonosetron buccal
- Research program: cannabis-based therapeutics
- TA-A002
- Ondansetron transdermal
Introduction
Executive Summary
Chemotherapy Induced Nausea and Vomiting: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chemotherapy Induced Nausea and Vomiting companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chemotherapy Induced Nausea and Vomiting Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
APD403: Acacia Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CAM2047: Camurus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
TA-A002: TALLC Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chemotherapy Induced Nausea and Vomiting Key Companies
Chemotherapy Induced Nausea and Vomiting Key Products
Chemotherapy Induced Nausea and Vomiting- Unmet Needs
Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
Chemotherapy Induced Nausea and Vomiting Analyst Views
Chemotherapy Induced Nausea and Vomiting Key Companies
Appendix
Executive Summary
Chemotherapy Induced Nausea and Vomiting: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chemotherapy Induced Nausea and Vomiting companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chemotherapy Induced Nausea and Vomiting Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
APD403: Acacia Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CAM2047: Camurus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
TA-A002: TALLC Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chemotherapy Induced Nausea and Vomiting Key Companies
Chemotherapy Induced Nausea and Vomiting Key Products
Chemotherapy Induced Nausea and Vomiting- Unmet Needs
Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
Chemotherapy Induced Nausea and Vomiting Analyst Views
Chemotherapy Induced Nausea and Vomiting Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chemotherapy Induced Nausea and Vomiting
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chemotherapy Induced Nausea and Vomiting
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chemotherapy Induced Nausea and Vomiting
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chemotherapy Induced Nausea and Vomiting
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
